Hypogonadism management and cardiovascular health

Auerbach, Jeremy M.; Khera, Mohit

doi:10.1080/00325481.2020.1805917

Cited by 4 publications

(2 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results show a strong correlation between hypogonadism and pathologic cardiovascular outcomes, as shown in Table 7 and Figure 2 (Survival Tables are available as Supplementary Materials). Previous studies have shown that there is an increased occurrence of heart failure, metabolic syndrome, insulin resistance, and diabetes mellitus in hypogonadal patients [20]. Furthermore, gonadal dysfunction may interfere in cholesterol levels [19].…”

Section: Discussionmentioning

confidence: 99%

The Influence of Cardiovascular Risk Factors and Hypogonadism on Cardiac Outcomes in an Aging Population of Beta-Thalassemia Patients

Barbero

Ajassa

Gaglioti

et al. 2021

JCDD

View full text Add to dashboard Cite

Beta-thalassemia major (β-TM) is a hereditary genetic disease worsened by many comorbidities due to transfusion-related iron despite chelation therapy. Since there has recently been an increase in life expectancy of patients to up to 50 years old, which influences the prevalence of these diseases and the time span for traditional cardiovascular risk factors to play their role, this study aims to evaluate their distribution and prevalence in a population of thalassemia major patients and their relationship with observed cardiovascular events and potential modifying factors. One hundred and fifty-nine β-TM patients with at least 15 years of follow-up were included in this study. The mean age was 40.9 ± 8.4 years; 28% had diabetes mellitus and 62% had hypogonadism. The cardiovascular risk assessed using algorithms (CUORE and Pooled Cohort Risk Equation—PCRE) was low, but 3.8% of patients had at least one episode of heart failure, 35.9% showed early signs of heart failure, 22% received a diagnosis of diastolic dysfunction, and 21.4% showed supraventricular arrhythmias. Hypogonadism was shown to be related to the occurrence of cardiovascular events. The chronic accumulation of iron in the heart and the specific metabolic profile, mainly observed in patients with hypogonadism, allows us to define β-TM as a condition with a high level of cardiovascular risk from many points of view (iron-related myopathy, atherosclerosis and arrhythmias), which requires better stratification tools and a specific follow-up program.

show abstract

Section: Discussionmentioning

confidence: 99%

The Influence of Cardiovascular Risk Factors and Hypogonadism on Cardiac Outcomes in an Aging Population of Beta-Thalassemia Patients

Barbero

Ajassa

Gaglioti

et al. 2021

JCDD

View full text Add to dashboard Cite

show abstract

“…The findings of this study provide robust evidence supporting the cardiovascular and long-term noncardiovascular safety and efficacy of SGLT2 inhibitors in the treatment of patients. The findings of Gager et al [ 27 ] concluded that SGLT2 inhibitors play a significant role in decreasing the risk of cardiovascular diseases, particularly in patients with heart failure (HF) [ 45 ]. This study also revealed that SGLT2 inhibitors demonstrated a 27% relative risk reduction in the composite outcome of hospitalization for HF or cardiovascular (CV) mortality, a 32% risk reduction in hospitalization for HF, an 18% risk reduction in CV mortality, and a 17% risk reduction in all-cause mortality.…”

Section: Reviewmentioning

confidence: 99%

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review

Moparthi,

Al Rushaidi,

Muddam

et al. 2023

Cureus

View full text Add to dashboard Cite

Cardiovascular disorders are one of the most frequent causes of death in people throughout the world. These disorders can account for the deaths of 31% of people worldwide. This systematic review examines the effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors in lowering the likelihood of cardiovascular diseases. The study aimed to evaluate various types of research, including randomized controlled trials and observational studies, to analyze how SGLT2 inhibitors impact cardiovascular disorders and establish evidence-based recommendations for clinical practice. The data in this research study were collected from 19 relevant published research articles. The key findings emphasized the potential advantages of SGLT2 inhibitors in reducing major cardiovascular disorders, such as myocardial infarction and stroke. Nonetheless, the study had certain limitations, including reliance on existing literature, exclusion of articles published prior to 2018, and restriction to English-language studies. Despite these limitations, this study contributed significantly to understanding the role of SGLT2 inhibitors in decreasing cardiovascular risk.

show abstract

Nutraceuticals and Phytotherapy in Men's Health: Antioxidants, Pro-oxidants, and a Novel Opportunity for Lifestyle Changes

Moyad

2022

Urologic Clinics of North America

View full text Add to dashboard Cite

Hypogonadism management and cardiovascular health

Cited by 4 publications

References 93 publications

The Influence of Cardiovascular Risk Factors and Hypogonadism on Cardiac Outcomes in an Aging Population of Beta-Thalassemia Patients

The Influence of Cardiovascular Risk Factors and Hypogonadism on Cardiac Outcomes in an Aging Population of Beta-Thalassemia Patients

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review

Nutraceuticals and Phytotherapy in Men's Health: Antioxidants, Pro-oxidants, and a Novel Opportunity for Lifestyle Changes

Contact Info

Product

Resources

About